On March 21, 2025, Dr. Jonathan Tian（田江森）, former Vice President of the Microsoft Asia Research Lab, visited ReBlood Group to explore the application of AI in health management. ReBlood Group announced a multi-million dollar investment to introduce Yushan AI and plans to establish an automated production laboratory and smart consulting services. This meeting aimed to promote cross-industry collaboration, focusing on large language models and edge computing technology while exploring innovations in health management. Dr. Tian shared his experiences at Microsoft and emphasized that AI can shift from data analysis to proactive intervention, enabling the commercialization of personalized aging reversal programs.
ReBlood CEO Sean Chen pointed out that the group has initiated pre-IPO preparations, and the collaboration with Yushan AI will accelerate its positioning in the Asia-Pacific market. Dr. Tian stressed that advancements in AI will change personal health management and enhance the accuracy and efficiency of preventive medicine. Both parties discussed how AI can be utilized to predict diseases early, creating new competitive advantages in the market.
The high-profile forum “How AI is Transforming the Health and Financial Industries,” scheduled for March 27, 2025, will feature ReBlood discussing trends in the application of AI in both health and financial sectors with leaders from industry, government, and academia. This meeting symbolizes a new milestone in cross-industry collaboration, and ReBlood looks forward to expanding cooperation to explore the broad application prospects of AI in the health industry.